Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and MMF Combination in Systemic Sclerosis-Associated Interstitial Lung Disease
NCT06549231Phase 3Recruiting
- Sponsor
- University Hospital Tours
- Start
- Jan 2025
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in systemic sclerosis-associated interstitial lung disease (SSc-ILD), sponsored by University Hospital Tours. Started Jan 2025; status: recruiting.
02
Drugs
rituximab
03
Conditions
systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Beyond the preview
Go deeper on NCT06549231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549231.